Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Expenses (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Operating Expenses readings, the most recent being $251.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 5.18% year-over-year to $251.1 million, compared with a TTM value of $948.4 million through Dec 2025, changed 0.21%, and an annual FY2025 reading of $948.4 million, changed 0.21% over the prior year.
  • Operating Expenses hit $251.1 million in Q4 2025 for Apellis Pharmaceuticals, up from $235.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $251.1 million in Q4 2025, with the low at $124.6 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $217.7 million (2023), compared with a mean of $204.1 million.
  • The sharpest move saw Operating Expenses soared 68.74% in 2021, then dropped 15.37% in 2022.
  • Year by year, Operating Expenses stood at $149.7 million in 2021, then grew by 24.73% to $186.7 million in 2022, then rose by 23.66% to $230.9 million in 2023, then rose by 3.38% to $238.7 million in 2024, then increased by 5.18% to $251.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $251.1 million, $235.4 million, and $211.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.